RecruitingNot applicableNCT05996731

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

Studying Atypical hemolytic uremic syndrome with complement gene abnormality

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Mario Negri Institute for Pharmacological Research
Principal Investigator: Marina Noris, PhD
Istituto Di Ricerche Farmacologiche Mario Negri
Intervention: Skin biopsy(procedure)
Enrollment: 105 enrolled
Eligibility: All sexes
Timeline: 2024 – 2026

Study locations (1)

Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò", Ranica, BG, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05996731 on ClinicalTrials.gov

← Back to all trials